Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. - Test2 - elhamkhani - TriplyDB

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

http://www.wikidata.org/entity/Q37443603

about

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors Engineered T cells for cancer treatment Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.New approach to develop ultra-high inhibitory drug using the power function of the stoichiometry of the targeted nanomachine or biocomplex.Discovery of a new method for potent drug development using power function of stoichiometry of homomeric biocomplexes or biological nanomotors Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling.Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer.Immunotargeting and personalized therapies in genitourinary cancers.

P2860

Q26778759-66E6ED9A-3497-4B85-AE47-7F8810BDD2B2 Q33578792-73CEB451-E253-4C6E-9B6F-6257093913BF Q33992425-DA11DEFD-46C4-4DAF-AF0D-7D285228D7F7 Q35980893-258807BB-CF87-477F-9C67-7CF9AB035F20 Q36192598-4B4AAC8D-1D09-4FC7-A6B0-D654EEAED0D3 Q36522581-3DBCF215-40C5-492C-8709-50DA6FD0528D Q38573837-AD36ADB2-EBF1-425D-83B8-BDB4C56EBA6E Q38964798-D037D53F-E3B9-4A7F-9BC1-3C8C700E1F7A Q39064900-1E924762-AA7E-46A3-A099-91A89C69AAD1 Q39093352-66EAE964-7C0D-42DE-9974-B26F63762219 Q42072059-650BD653-E9D7-42A1-807F-34173285B3FC Q48133624-1A9AC988-765F-4A29-9F06-8F03232A76A6

P2860

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

http://www.wikidata.org/entity/Q37443603

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 January 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

@en

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

@nl

type

label

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

@en

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

@nl

prefLabel

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

@en

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

@nl

P1433

Q37443603-BBC9C9BC-E8D6-4800-BA6F-46B439C6D4A2

P1476

Q37443603-F3FA53F3-614B-40F1-AF41-7D88698F6119

P2093

Q37443603-22FAD26E-0740-423B-B0D5-87E37B578F73

Q37443603-2BECC4E3-AA98-44C8-B8E0-A9E22B946586

Q37443603-37DFBF57-05FA-48C4-9F5E-7AF40ED28C76

Q37443603-383E0492-0E83-4A98-8196-C543453EC82E

Q37443603-5F0EACD1-5447-4A36-9880-5C788648E4D8

Q37443603-82BA0341-DC28-4E4A-9316-F56688AD41D8

Q37443603-8316CD41-724B-486C-ADE0-FA2FF5B9E646

Q37443603-98DEB84F-AA4D-4C9E-B4EF-075915B1E467

Q37443603-A4ECA387-C550-4F95-81D6-C056D090CEF3

Q37443603-FEDE36E3-1BEB-4A3B-B667-2397426EF653

P2860

Q37443603-096100F4-7A93-4C52-9CE9-990A1DABFA1F

Q37443603-1794D4E9-EBC7-4D14-9486-CA559D735EA9

Q37443603-1CD5E4B4-C8F1-49EA-B3C4-1B15C4F0C7CE

Q37443603-1F5E5E08-009B-4268-9EB9-CCCDAF400352

Q37443603-20142991-DE4D-4350-AD6C-8468172AA39F

Q37443603-2452FB61-F72F-4E80-A327-9B77DBA3698C

Q37443603-25380BF7-1C9F-4172-A314-9B29F44BB195

Q37443603-3774A1AD-E5A5-440D-983A-162CEE712F66

Q37443603-3E29A64A-1411-4B7E-ADBE-8CEFC34EAA33

Q37443603-3E765A0F-A6F8-4B2D-9D17-0DD9B4595679

P2888

Q37443603-75EEFA9E-974F-4325-9B97-F1DACAB06134

P304

Q37443603-8150457D-057D-482D-9548-7355EE8860CD

P31

Q37443603-66B7E666-7F73-41DB-836A-9E8CF6A19992

P356

Q37443603-14FD5D53-9806-486C-8C27-ECA763A39147

P433

Q37443603-67390FDA-2EAE-45FF-94A4-B308FDC6D09E

P478

Q37443603-131048D0-B347-44E9-B25C-CA49A7B99926

P577

Q37443603-1D71F1E6-2859-4FA6-BE2B-04B48E1B3679

P698

Q37443603-8930E1ED-A272-43E3-99EB-CACC8CDA7837

P921

Q37443603-2E511F45-9E9D-42EA-927D-7A8D90702425

P932

Q37443603-F8FD8C1A-A0D5-4E3F-A506-DB6A909379A6

P356

P1433

Prostate Cancer and Prostatic Diseases

P1476

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

@en

P2093

A M Leen

http://www.w3.org/2001/XMLSchema#string

C M Rooney

http://www.w3.org/2001/XMLSchema#string

C Sanchez

http://www.w3.org/2001/XMLSchema#string

G Palapattu

http://www.w3.org/2001/XMLSchema#string

J F Vera

http://www.w3.org/2001/XMLSchema#string

M K Brenner

http://www.w3.org/2001/XMLSchema#string

M Mims

http://www.w3.org/2001/XMLSchema#string

P Bajgain

http://www.w3.org/2001/XMLSchema#string

R Chan

http://www.w3.org/2001/XMLSchema#string

S Rambally

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

MUC1 is a promising therapeutic target for prostate cancer therapy

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

P2888

P304

123-31, S1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/PCAN.2012.49

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23295316

http://www.w3.org/2001/XMLSchema#string

P921

P932

3883310

http://www.w3.org/2001/XMLSchema#string